Posted on

China-Nepal Railway

China-Nepal Railway aims to connect China’s Tibet Autonomous Region (specifically Shigatse, an extension of the existing Qinghai-Tibet Railway) with Kathmandu, the capital of Nepal. It’s envisioned as a “game-changer” for Nepal, transforming it from a landlocked to a “land-linked” country and enhancing connectivity with China and South Asia. https://www.facebook.com/jeff.mah.5/videos/1195426962128005/?__cft__[0]=AZU-4mw3YbLdh6P6Z7OIsVGzwwHhCtsbvlK35bB-zkiUGsKuO3V5e_Otoi3UmGJbIZ70YhltdxxTdQHyWQjCSvhR2QwrD_IfXzwTPcIwviKOVAzUZuMUFnnGi-GIFeVQ-5_lKvipQ355_J8dFthHSxVnSNoFheRZMDjCPBkBQ9ic8A&__tn__=%2CO%2CP-R

Posted on

Pfizer-3S Bio Deal

Pfizer has entered into a licensing agreement with China’s 3S Bio for a cancer drug that utilizes bi-specific antibody technology, targeting PD1 and VEGF. 3S Bio is currently conducting clinical trials for this drug in China, focusing on non-small cell lung cancer, colorectal cancer, and gynecological tumors. Pfizer will pay 3S Bio $1.25 billion upfront and potentially up to $4.8 billion for the rights to develop and sell the drug outside of China. https://www.facebook.com/jeff.mah.5/videos/731145832811561/?__cft__[0]=AZUlCfwFY-atEdbJ_ODrJyPiY7An2ZxgrViHYXeCCzoRUjHIDGVE_tpTW-jbIkX4pCb9ggCnqE17eP8B7h643_ZJguYxphEAxlRqwiVUjhskLuqD88vgUylrW9oOQnd_SbXjfPlpv5pvsaJEsXuzvr69JfEQQJCI3_-U2XPlReG3NQ&__tn__=%2CO%2CP-R